SwePub
Tyck till om SwePub Sök här!
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Hjorth Hansen Henrik) ;pers:(Guilhot Joelle)"

Sökning: WFRF:(Hjorth Hansen Henrik) > Guilhot Joelle

  • Resultat 1-6 av 6
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  •  
3.
  •  
4.
  • Saussele, Susanne, et al. (författare)
  • Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI) : a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
  • 2018
  • Ingår i: The Lancet Oncology. - : Elsevier. - 1470-2045 .- 1474-5488. ; 19:6, s. 747-757
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Tyrosine kinase inhibitors (TKIs) have improved the survival of patients with chronic myeloid leukaemia. Many patients have deep molecular responses, a prerequisite for TKI therapy discontinuation. We aimed to define precise conditions for stopping treatment. Methods: In this prospective, non-randomised trial, we enrolled patients with chronic myeloid leukaemia at 61 European centres in 11 countries. Eligible patients had chronic-phase chronic myeloid leukaemia, had received any TKI for at least 3 years (without treatment failure according to European LeukemiaNet [ELN] recommendations), and had a confirmed deep molecular response for at least 1 year. The primary endpoint was molecular relapse-free survival, defined by loss of major molecular response (MMR; >0·1% BCR-ABL1 on the International Scale) and assessed in all patients with at least one molecular result. Secondary endpoints were a prognostic analysis of factors affecting maintenance of MMR at 6 months in learning and validation samples and the cost impact of stopping TKI therapy. We considered loss of haematological response, progress to accelerated-phase chronic myeloid leukaemia, or blast crisis as serious adverse events. This study presents the results of the prespecified interim analysis, which was done after the 6-month molecular relapse-free survival status was known for 200 patients. The study is ongoing and is registered with ClinicalTrials.gov, number NCT01596114. Findings: Between May 30, 2012, and Dec 3, 2014, we assessed 868 patients with chronic myeloid leukaemia for eligibility, of whom 758 were enrolled. Median follow-up of the 755 patients evaluable for molecular response was 27 months (IQR 21–34). Molecular relapse-free survival for these patients was 61% (95% CI 57–64) at 6 months and 50% (46–54) at 24 months. Of these 755 patients, 371 (49%) lost MMR after TKI discontinuation, four (1%) died while in MMR for reasons unrelated to chronic myeloid leukaemia (myocardial infarction, lung cancer, renal cancer, and heart failure), and 13 (2%) restarted TKI therapy while in MMR. A further six (1%) patients died in chronic-phase chronic myeloid leukaemia after loss of MMR and re-initiation of TKI therapy for reasons unrelated to chronic myeloid leukaemia, and two (<1%) patients lost MMR despite restarting TKI therapy. In the prognostic analysis in 405 patients who received imatinib as first-line treatment (learning sample), longer treatment duration (odds ratio [OR] per year 1·14 [95% CI 1·05–1·23]; p=0·0010) and longer deep molecular response durations (1·13 [1·04–1·23]; p=0·0032) were associated with increasing probability of MMR maintenance at 6 months. The OR for deep molecular response duration was replicated in the validation sample consisting of 171 patients treated with any TKI as first-line treatment, although the association was not significant (1·13 [0·98–1·29]; p=0·08). TKI discontinuation was associated with substantial cost savings (an estimated €22 million). No serious adverse events were reported. Interpretation: Patients with chronic myeloid leukaemia who have achieved deep molecular responses have good molecular relapse-free survival. Such patients should be considered for TKI discontinuation, particularly those who have been in deep molecular response for a long time. Stopping treatment could spare patients from treatment-induced side-effects and reduce health expenditure. Funding: ELN Foundation and France National Cancer Institute.
  •  
5.
  • Söderlund, Stina, et al. (författare)
  • Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukaemia patients stopping tyrosine kinase inhibitor therapy
  • 2020
  • Ingår i: Leukemia research. - : PERGAMON-ELSEVIER SCIENCE LTD. - 0145-2126 .- 1873-5835. ; 90
  • Tidskriftsartikel (refereegranskat)abstract
    • Several studies have now shown that chronic myeloid leukaemia (CML) patients in deep molecular remission may discontinue tyrosine kinase inhibitor (TKI) treatment with a treatment free remission (TFR) rate of approximately 40-60 %. Some factors influencing the possibility of TFR have been described but better tools are needed for individual prediction of long-term TFR. Herein, two multiplex panels were utilised to analyse a total of 162 different plasma proteins from 56 patients included in the TKI stopping trial EURO-SKI (Saussele a al., 2018). The purpose was to identify possible plasma protein markers for prediction of successful TKI discontinuation and to evaluate effects of TKI discontinuation on plasma protein profiles. No protein biomarkers sampled before TKI discontinuation could separate relapse cases from non-relapse cases but some plasma proteins differed between patients who relapsed and those who remained in TFR when followed over time after TKI cessation. In conclusion, the plasma protein markers in this study could not predict relapse after TKI discontinuation but may be of use to understand the mechanisms involved in maintenance of TFR.
  •  
6.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-6 av 6
Typ av publikation
tidskriftsartikel (5)
annan publikation (1)
Typ av innehåll
övrigt vetenskapligt/konstnärligt (4)
refereegranskat (2)
Författare/redaktör
Richter, Johan (6)
Saussele, Susanne (6)
Guilhot, Joelle (6)Ta bort avgränsningen
Hjorth-Hansen, Henri ... (6)
Mustjoki, Satu (6)
Olsson-Strömberg, Ul ... (5)
visa fler...
Ehrencrona, Hans (4)
Mahon, Francois-Xavi ... (4)
Söderlund, Stina (4)
Koskenvesa, Perttu (4)
Muller, Martin C. (4)
Porkka, Kimmo (3)
Pfirrmann, Markus (3)
Malm, Claes (2)
Persson, Inger (2)
Höglund, Martin (2)
Lehmann, Soren (2)
Mayer, Jiri (2)
Almeida, Antonio (2)
Kairisto, Veli (2)
Själander, Anders (2)
Markevärn, Berit (2)
Ohm, Lotta (2)
Ekblom, Marja (2)
Stenke, Leif (2)
Lübking, Anna (2)
Lotfi, Kourosh (2)
Majeed, Waleed (2)
Holm, Elena (2)
Ilander, Mette (2)
Vestergaard, Hanne (1)
Hochhaus, Andreas (1)
Rousselot, Philippe (1)
Panayiotidis, Panayi ... (1)
Martinez-Lopez, Joaq ... (1)
Janssen, Jeroen J W ... (1)
Ossenkoppele, Gert J (1)
Hofmann, Wolf-Karste ... (1)
Bryceson, Yenan (1)
Loskog, Angelica (1)
Strömberg, Ulla Ohls ... (1)
Schlums, Heinrich (1)
Gruber, Franz X. (1)
Kasanen, Tiina (1)
Bjoreman, Mats (1)
Lahteenmaki, Hanna (1)
Ilander, Mette Matil ... (1)
Tiina, Kasanen (1)
Lahteenmäki, Hanna (1)
Björeman, Mats (1)
visa färre...
Lärosäte
Uppsala universitet (6)
Umeå universitet (2)
Lunds universitet (1)
Karolinska Institutet (1)
Språk
Engelska (6)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (6)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy